Skip to main content

Poolbeg Pharma upbeat on preliminary influenza drug results

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

--News Direct--

Poolbeg Pharma PLC (OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after announcing initial data analysis, including a 'clear dose-related response', for its drug, POLB 001, a potential treatment for severe influenza. Skillington says the 'early data readout' indicates that the challenge trial was successful.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/poolbeg-pharma-upbeat-on-preliminary-influenza-drug-results-758545326

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  242.85
+1.15 (0.48%)
AAPL  301.96
+7.58 (2.58%)
AMD  534.87
-6.01 (-1.11%)
BAC  58.22
-0.14 (-0.24%)
GOOG  359.68
+1.79 (0.50%)
META  594.01
-18.90 (-3.08%)
MSFT  386.16
+1.88 (0.49%)
NVDA  198.37
+0.79 (0.40%)
ORCL  145.84
+3.34 (2.34%)
TSLA  413.66
-11.64 (-2.74%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.